GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Net Income

Pharmaresearch Bio Co (XKRX:217950) Net Income : ₩2,308 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Pharmaresearch Bio Co's Net Income for the six months ended in Dec. 2023 was ₩2,308 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was ₩2,308 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Pharmaresearch Bio Co's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was ₩568.98.


Pharmaresearch Bio Co Net Income Historical Data

The historical data trend for Pharmaresearch Bio Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co Net Income Chart

Pharmaresearch Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial -851.22 21.23 2,310.52 7,418.26 2,308.35

Pharmaresearch Bio Co Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Get a 7-Day Free Trial -851.22 21.23 2,310.52 7,418.26 2,308.35

Pharmaresearch Bio Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Pharmaresearch Bio Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=4640.32+-2331.971+0+4.5474735088646E-13
=2,308

Pharmaresearch Bio Co's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=4640.32+-2331.971+0+4.5474735088646E-13
=2,308

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was ₩2,308 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaresearch Bio Co  (XKRX:217950) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Pharmaresearch Bio Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Pharmaresearch Bio Co Net Income Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaresearch Bio Co (XKRX:217950) Business Description

Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines